Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease

Peritoneal Malignant Disease (PMD) is the presence of tumoral tissue on the peritoneal surface from primary tumors or tumors from other locations (e.g. digestive or gynecologic). It is a regional disease with poor prognosis when treated with repeated “debulking” and traditional systemic chemotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2010-12, Vol.12 (12), p.794-804
Main Authors: Vásquez Jiménez, Wenceslao, González Bayón, Luis, García-Sabrido, José Luis, González Moreno, Santiago
Format: Article
Language:English
Subjects:
Aged
Chemotherapy, Cancer, Regional Perfusion - methods
Combined Modality Therapy
Educational Series/Red Series
Humans
Hyperthermia, Induced - methods
Injections, Intraperitoneal
Medicine
Medicine & Public Health
Oncology
Peritoneal Neoplasms - pathology
Peritoneal Neoplasms - surgery
Peritoneal Neoplasms - therapy
Peritoneum - pathology
Peritoneum - surgery
Prognosis
Survival Rate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peritoneal Malignant Disease (PMD) is the presence of tumoral tissue on the peritoneal surface from primary tumors or tumors from other locations (e.g. digestive or gynecologic). It is a regional disease with poor prognosis when treated with repeated “debulking” and traditional systemic chemotherapy. Cytoreduction plus hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined multimodal regional procedure aimed at reducing the macroscopic tumoral mass as much as possible and treating with chemotherapy the microscopic disease that is out of the scope of the surgeon. This combined treatment may change the natural history of PMD, it is translated into a higher overall survival and cancer-free survival and it offers the option of cure in selected cases. The high-complexity procedure is also associated with complications and mortality, but in similar rates as other major oncologic procedures.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-010-0601-x